Skip to content

Cancer Health Center

Font Size

Renal Cell Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (08 / 02 / 2013)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Stage IV and Recurrent Renal Cell Cancer

Recommended Related to Cancer


This complementary and alternative medicine (CAM) information summary provides an overview of the use of antineoplastons as treatments for people with cancer. The summary includes a brief history of the development of antineoplastons; a review of laboratory, animal, and human studies; and possible side effects associated with antineoplaston use. This summary contains the following key information: Antineoplastons are drugs composed of chemical compounds that are naturally present in the urine...

Read the Overview article > >

Added Motzer et al. as reference 30. Revised text to state that the primary endpoint was progression-free survival (PFS), and the data were analyzed when disease in 88% of the axitinib patients and 90% of the sorafenib patients had progressed, while 58% and 59%, respectively, had died.

Revised text to state that median PFS was 8.3 months for axitinib and 5.7 months for sorafenib, and median overall survival (OS) was 20.1 months with axitinib versus 19.2 months with sorafenib; however, the largest benefit was seen in patients who received cytokines as first-line therapy and whose median PFS was 12.2 months with axitinib compared with 8.2 months with sorafenib, while median overall survival was 29.4 months with axitinib compared with 27.8 months with sorafenib. Also added that in contrast, in patients who had previously received sunitinib, axitinib was associated with a 2.1-month increase in PFS compared with sorafenib, but median OS was nearly identical: 15.2 months with axitinib compared with 16.5 months with sorafenib.

Revised text to state that comparing the toxicity of the axitinib and sorafenib regimens is complicated.

Added text to include axitinib on the list of single or combination therapies for which there are ongoing clinical trials to which patients might be directed.

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http:// cancer .gov or call 1-800-4-CANCER.

    WebMD Public Information from the National Cancer Institute

    Last Updated: September 04, 2014
    This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
    Next Article:

    Today on WebMD

    Colorectal cancer cells
    New! I AM Not Cancer Facebook Group
    Lung cancer xray
    See it in pictures, plus read the facts.
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Ovarian cancer illustration
    Real Cancer Perspectives
    Jennifer Goodman Linn self-portrait
    what is your cancer risk
    colorectal cancer treatment advances
    breast cancer overview slideshow
    prostate cancer overview
    lung cancer overview slideshow
    ovarian cancer overview slideshow
    Actor Michael Douglas